Domača stranCRSP • NASDAQ
add
Crispr Therapeutics AG
Prejšnji trg. dan.
41,29 $
Dnevni razpon
38,51 $ - 40,37 $
Letni razpon
38,20 $ - 91,10 $
Tržna kapitalizacija
3,39 mrd. USD
Povprečni obseg
1,79 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 602,00 tis. | — |
Stroški poslovanja | 17,42 mio. | −4,77 % |
Čisti dohodek | −85,94 mio. | 23,37 % |
Čista dobičkovnost prihodkov | −14,28 tis. | — |
Earnings per share | −1,01 | 28,37 % |
EBITDA | −105,39 mio. | 17,33 % |
Efektivna davčna stopnja | −1,03 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 1,94 mrd. | 11,26 % |
Skupna sredstva | 2,26 mrd. | 8,11 % |
Skupne obveznosti | 316,47 mio. | −11,86 % |
Celoten lastniški kapital | 1,94 mrd. | — |
Shares outstanding | 85,35 mio. | — |
Razmerje P/B | 1,82 | — |
Donosnost sredstev | −11,98 % | — |
Donosnost kapitala | −12,57 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −85,94 mio. | 23,37 % |
Denar iz dejavnosti | −106,91 mio. | −168,25 % |
Denar iz naložb | −161,60 mio. | −233,17 % |
Denar iz financiranja | 9,64 mio. | 519,54 % |
Neto sprememba denarnih sredstev | −258,80 mio. | −411,81 % |
Prost denarni tok | −80,67 mio. | −495,63 % |
Vizitka
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Datum ustanovitve
2013
Sedež organizacije
Spletno mesto
Zaposleni
407
